ArticleSurgical endoscopy2026
Multi-label dynamic diagnosis of pancreatic diseases using AI-enhanced endoscopic ultrasound: a multi-cohort real-world study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundArtificial intelligence (AI) is a promising tool for pancreatic disease diagnosis using Endoscopic Ultrasound (EUS) images. But, current models often fail to fully account for real-world clinical applicability. To address this limitation, we propose the multi-label, dynamic AI system, designed to mimic real-world physician assessments.
methodsWe included 2 783 patients (330 706 EUS images) from three cohorts: FUSCC training (n = 2 498), FUSCC internal testing (n = 178), and external testing (n = 107). The AI-Enhanced Pancreatic Multi-Disease Diagnostic System with EUS (AI-Paradise) integrates module 1 (image type classification), module 2 (image quality control), and module 3 (multi-label classification). A computer-assisted diagnostic test (CADT) assessed the diagnostic performance of endoscopists with AI-Paradise assistance.
resultsModule 1 and Module 2 achieved mean accuracies of 79·0 and 94·7%, respectively. These modules filtered out low-quality images, selecting 81 540 B-mode images for Module 3. In internal cross-validation, the best area under the curve (AUC) for six pancreatic diseases ranged from 71·5 to 87·6%. Module 3 demonstrated strong per-disease diagnostic performance in image-level testing, with accuracies ranging from 73.3 to 85.5% for the six pancreatic diseases (Table 2). The overall patient-level correct diagnosis rates, which are secondary summary metrics, were 66.9% (internal) and 63.6% (external). In CADT, performance of novice endoscopists significantly improved, with the best-performing novice achieving an increase from 39·4 to 57·4% (p < 0·0001).
conclusionsAI-Paradise enhances diagnostic performance by assisting endoscopists in filtering out low-quality images and making accurate multiple-disease diagnoses.
Indexed as
Identifiers
42310197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.